CVS Surges: Turnaround Fuels 57% Stock Jump

CVS Health has demonstrated impressive performance, with its stock appreciating by 57% over the last 12 months. As of July 6, 2026, shares closed at $103.61, marking a significant year-to-date gain. The company's valuation, with a forward P/E of 14, remains attractive relative to its earnings potential and the broader healthcare sector.

The first quarter of 2026 proved to be a pivotal period for CVS Health. The company reported adjusted earnings per share of $2.57, significantly beating the consensus estimate of $2.21. This outperformance was largely attributed to the successful turnaround of its Aetna segment, which saw a substantial increase in operating income and an improved medical benefit ratio. Following this strong report, CVS Health's management enhanced its full-year financial projections, forecasting adjusted EPS between $7.30 and $7.50 and operating cash flow of at least $9.5 billion.

CEO David Joyner is actively pursuing an integrated healthcare strategy, aiming to engage with millions of individuals. The company is also introducing new opportunities in the GLP-1 market, including a Medicare GLP-1 Bridge program and virtual weight-management services. These strategic moves reflect CVS Health's commitment to innovation and expanding its service offerings to meet evolving patient needs.